RT Book, Section
A1 Bahl, Vinay K.
A1 Math, Ravi S.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1161731957
T1 ANTITHROMBOTIC THERAPY FOR VALVULAR HEART DISEASE
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1161731957
RD 2024/04/23
AB The  worldwide  burden  of  valvular  heart  disease  (VHD)  continues  to  grow  as  a  result  of  increases  in  life  expectancy  combined  with  the  high  incidence  of  rheumatic  heart  disease  in  developing  nations.1  Patients  with  VHD  and  certain  comorbid  conditions  or  prosthetic  heart  valves  (PHVs)  are  at  high  risk  for  thromboembolic  complications  and  often  require  antithrombotic  therapy  (Table  53–1).  Although  bleeding  is  a  risk  with  all  antithrombotic  agents,  the  frequency  and  consequences  of  a  stroke  make  drug  therapy  appropriate  in  many  patients  with  VHD.2